Sandoz, a Novartis division, announced that the European Commission granted marketing authorization for “the first and only biosimilar” Tyruko, developed by Polpharma Biologics. The authorization covers treatment as a single disease-modifying therapy in adults with highly active RRMS, the same indication as approved by the EC for the reference medicine Tysabri, the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Novartis reports Phase 3 NETTER-2 trial met primary endpoint
- Novartis confirms Sandoz spin-off for October 4
- Novartis upgraded to Equal Weight from Underweight at Morgan Stanley
- Novartis’ Sandoz gets FDA approval for intravenous Cyclophosphamide Injection
- BeiGene announces positive regulatory updates in Europe, U.S.